Vicapsys Life Sciences annual shareholders’ equity
2019
2020
2021
2022
2023
Vicapsys Life Sciences Shareholders’ Equity Growth & History (VICP)
Vicapsys Life Sciences's shareholders’ equity was −$1.9M for fiscal 2023.
View full Vicapsys Life Sciences company overviewVicapsys Life Sciences annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-12-31 | −$1.9M | −$977,890 | — |
| 2022 | 2022-12-31 | −$950,791 | −$829,140 | — |
| 2021 | 2021-12-31 | −$121,651 | $327,455 | — |
| 2020 | 2020-12-31 | −$449,106 | −$751,063 | — |
| 2019 | 2019-12-31 | $301,957 | — | — |
Vicapsys Life Sciences quarterly shareholders’ equity
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q3 2024 | 2024-09-30 | −$2.6M | −$1.3M | — |
| Q2 2024 | 2024-06-30 | −$2.4M | −$1.4M | — |
| Q1 2024 | 2024-03-31 | −$2.3M | −$1.1M | — |
| Q4 2023 | 2023-12-31 | −$1.9M | −$977,890 | — |
| Q3 2023 | 2023-09-30 | −$1.3M | −$813,600 | — |
| Q2 2023 | 2023-06-30 | −$1.1M | −$626,946 | — |
| Q1 2023 | 2023-03-31 | −$1.1M | −$857,302 | — |
| Q4 2022 | 2022-12-31 | −$950,791 | −$829,140 | — |
| Q3 2022 | 2022-09-30 | −$520,278 | −$326,403 | — |
| Q2 2022 | 2022-06-30 | −$466,592 | −$207,817 | — |
| Q1 2022 | 2022-03-31 | −$287,617 | $110,177 | — |
| Q4 2021 | 2021-12-31 | −$121,651 | $327,455 | — |
| Q3 2021 | 2021-09-30 | −$193,875 | $175,764 | — |
| Q2 2021 | 2021-06-30 | −$258,775 | $35,341 | — |
| Q1 2021 | 2021-03-31 | −$397,794 | −$340,700 | — |
| Q4 2020 | 2020-12-31 | −$449,106 | −$751,063 | — |
| Q3 2020 | 2020-09-30 | −$369,639 | — | — |
| Q2 2020 | 2020-06-30 | −$294,116 | — | — |
| Q1 2020 | 2020-03-31 | −$57,094 | — | — |
| Q4 2019 | 2019-12-31 | $301,957 | — | — |
Vicapsys Life Sciences shareholders’ equity trends
Between the periods ended 2019-12-31 and 2023-12-31, Vicapsys Life Sciences's shareholders’ equity decreased from $301,957 to −$1.9M, a change of −$2.2M. The latest reported quarter, Q3 2024, shows −$2.6M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vicapsys Life Sciences source filings ↗